MAPPs and New Benefit Risk Models: IMI2 Leads with Patient Engagement in 5th Call for Proposals

The Innovative Medicines Initiative (IMI) yesterday launched its 5th Call for proposals under the IMI 2 programme.  Topic 1 addresses one of the key enablers of adaptive pathways – developing methods to incorporate the input of patients into the assessments of benefits and risks of new medicines at all stages of the drug development life cycle.

Read More